SciSparc Ltd. (SPRC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders, has announced a non-binding letter of intent to sell its majority stake in MitoCareX Bio for a potential total of $8 million, reflecting a 47% increase in valuation since its initial investment. The transaction, which includes milestone-based increments to the consideration, is aimed at enhancing shareholder value and aligns with SciSparc’s strategic focus on investment and partnership opportunities.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.
